Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Pamela D. Garzone will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will focus on the company's Phase 1 clinical trial of their ovarian cancer CAR-T immunotherapy.

The poster, led by Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator of the trial, will discuss the study of autologous T-cells genetically engineered to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation is scheduled for June 2, 2025, from 1:30 PM to 4:30 PM CT.

SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois. Lead author on the poster is Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy.

Presentation Details:

• Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)
• Session: Developmental Therapeutics—Immunotherapy
• Session Type: Poster Session
• Date & Time: June 2, 2025, 1:30 PM – 4:30 PM CT
• Abstract ID: TPS2682

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-poster-presentation-on-ovarian-cancer-car-t-clinical-trial-at-the-american-society-of-clinical-oncology-asco-annual-meeting-302450113.html

SOURCE Anixa Biosciences, Inc.

FAQ

What will Anixa Biosciences (ANIX) present at ASCO 2025?

Anixa will present a poster on their Phase 1 clinical trial of CAR-T immunotherapy for recurrent ovarian cancer, focusing on T-cells engineered to target the follicle-stimulating hormone receptor (FSHR).

When and where is Anixa's (ANIX) ASCO 2025 presentation scheduled?

The presentation is scheduled for June 2, 2025, from 1:30 PM to 4:30 PM CT at the ASCO Annual Meeting in Chicago, Illinois.

Who are the key presenters for Anixa's (ANIX) ASCO 2025 poster?

Dr. Pamela D. Garzone, Anixa's Chief Development Officer, will present the poster, with Dr. Robert Wenham, Chair of Moffitt Cancer Center's Gynecologic Oncology Program, as lead author.

What type of cancer treatment is Anixa Biosciences (ANIX) developing?

Anixa is developing a CAR-T immunotherapy treatment that uses genetically engineered T-cells targeting the follicle-stimulating hormone receptor (FSHR) for recurrent ovarian cancer.